These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 5075673)

  • 1. The use of radioisotopically labelled compounds in drug substance and formulated product stability studies. II. Application to pharmaceutical formulations.
    Hudson HE; Jones MF
    Analyst; 1972 Sep; 97(158):726-7. PubMed ID: 5075673
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of radioisotopically labelled compounds in drug substance and formulated product stability studies. I. Studies with the drug substance.
    Hudson HE; Jones MF
    Analyst; 1972 Sep; 97(158):723-5. PubMed ID: 5075672
    [No Abstract]   [Full Text] [Related]  

  • 3. [Injectable hospital preparation of valine labeled with the carbon 13 and nitrogen 15 (5 mg/mL) for a clinical trial on the brain tumor metabolism: Pharmaceutical control of active pharmaceutical ingredient and stability study of the finished product].
    Tall ML; Diouf E; Filali S; Sauvinet V; Laleye D; Dhelens C; Salmon D; Gabert L; Nugue G; Sandre-Balester C; Berger F; Pirot F; Pivot C
    Ann Pharm Fr; 2015 Sep; 73(5):361-77. PubMed ID: 25747724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel method to radiolabel gastric retentive formulations for gamma scintigraphy assessment.
    Burke MD; Staton JS; Vickers AW; Peters EE; Coffin MD
    Pharm Res; 2007 Apr; 24(4):695-704. PubMed ID: 17372696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable isotope-labeled excipients for drug product identification and counterfeit detection.
    Felton LA; Shah PP; Sharp Z; Atudorei V; Timmins GS
    Drug Dev Ind Pharm; 2011 Jan; 37(1):88-92. PubMed ID: 20560792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and Stability of Solutions.
    Akers MJ
    Int J Pharm Compd; 2016; 20(1):41-5. PubMed ID: 27127830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations.
    VandenBussche HL; Johnson CE; Yun J; Patel SA
    Am J Health Syst Pharm; 2002 Oct; 59(19):1853-5. PubMed ID: 12374070
    [No Abstract]   [Full Text] [Related]  

  • 8. Vitamins in pharmaceutical formulations.
    DeRitter E
    J Pharm Sci; 1982 Oct; 71(10):1073-96. PubMed ID: 6754906
    [No Abstract]   [Full Text] [Related]  

  • 9. Overview of drug product development.
    Narayan P
    Curr Protoc Pharmacol; 2011 Dec; Chapter 7():Unit 7.3.1-29. PubMed ID: 22147349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASHP technical assistance bulletin on compounding nonsterile products in pharmacies. American Society of Hospital Pharmacists.
    Am J Hosp Pharm; 1994 Jun; 51(11):1441-8. PubMed ID: 7942879
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictive and Accelerated Formulation Design Using Synchrotron Methods.
    Byrn SR; Chen XS; Smith PA
    AAPS PharmSciTech; 2019 Apr; 20(5):176. PubMed ID: 31037517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preformulation studies in a drug development program for tablet formulations.
    Graffner C; Johansson ME; Nicklasson M; Nyqvist H
    J Pharm Sci; 1985 Jan; 74(1):16-20. PubMed ID: 3981410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of Maillard's reaction in pharmaceutical preparations].
    Pellerin F; Baylocq D; Mancheron D
    Ann Pharm Fr; 1971 Nov; 29(11):529-32. PubMed ID: 5138615
    [No Abstract]   [Full Text] [Related]  

  • 14. Co-former selection for co-amorphous drug-amino acid formulations.
    Kasten G; Löbmann K; Grohganz H; Rades T
    Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissolution test for liquid formulations of omeprazole enteric-coated products.
    Jang HJ; Kang BC; Shin WG; Lee S
    Ann Pharmacother; 2003 Jan; 37(1):150-1. PubMed ID: 12503954
    [No Abstract]   [Full Text] [Related]  

  • 16. 99mTc-HMPAO-labeled liposomes: an investigation into the effects of some formulation factors on labeling efficiency and in vitro stability.
    Mirahmadi N; Babaei MH; Vali AM; Daha FJ; Kobarfard F; Dadashzadeh S
    Nucl Med Biol; 2008 Apr; 35(3):387-92. PubMed ID: 18355695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of mechanical comminution on drug stability.
    Waltersson JO; Lundgren P
    Acta Pharm Suec; 1985; 22(5):291-300. PubMed ID: 4091000
    [No Abstract]   [Full Text] [Related]  

  • 18. Key considerations for optimization of formulation and melt-extrusion process parameters for developing thermosensitive compound.
    Ghosh I; Vippagunta R; Li S; Vippagunta S
    Pharm Dev Technol; 2012; 17(4):502-10. PubMed ID: 21284576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical Cocrystal Drug Products: An Outlook on Product Development.
    Shaikh R; Singh R; Walker GM; Croker DM
    Trends Pharmacol Sci; 2018 Dec; 39(12):1033-1048. PubMed ID: 30376967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.
    Sosabowski JK; Lee M; Dekker BA; Simmons BP; Singh S; Beresford H; Hagan SA; McKenzie AJ; Mather SJ; Watson SA
    Eur J Pharm Sci; 2007 Jun; 31(2):102-11. PubMed ID: 17387005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.